Amarin Corp Plc (AMRN)

[heysfguy]

It seems only natural to assume that if Vascepa's methods of action are anti-inflammatory, then it will have positive effects in more than lipid management issues. Reduced T's are likely a real marker, but perhaps not in the sense originally envisioned when the SPA was signed.

Regardless of FDA's repeated blunders - intentional or unintentional - we are seeing more and more evidence to support the use of Vascepa for a range of conditions, in addition to the CV arena.

As long as AMRN continues to make regulatory and fiscal progress, I have every confidence that we are on the cusp of great success not just as investors, but as potential patients. (Disclosure: I also have a less-than-satisfactory lipid profile.)

I have always felt that the AdCom debacle was intentionally orchestrated to delay AMRN's success, under the guise of protecting patients from ineffective drugs. In addition, I have always suspected that the potential rewards of EPA were so great that strong hands wanted weaker ones out of the pool, and they used whatever influence they had to convince the FDA that Vascepa did not deserve special consideration, including the SPA.

I would not be surprised to see much higher levels of institutional ownership in the very near future. And I expect some nice uptick in prescriptions soon, too. (Even my GP is starting to sound interested.)

Thanks again to frequent posters who have attempted to bring real knowledge to the board. Some of them may have strong personalities at times, but it comes with the territory!